Fintel reports that on April 7, 2025, HC Wainwright & Co. initiated coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with a ...

H.C. Wainwright analyst Scott Buck lowered the firm’s price target on Knightscope (KSCP) to $12 from $16 and keeps a Buy rating on the shares.

H.C. Wainwright lowered the firm’s price target on Bicara Therapeutics (BCAX) to $44 from $45 and keeps a Buy rating on the shares following the ...

HC Wainwright reiterated their buy rating on shares of Sensus Healthcare (NASDAQ:SRTS – Free Report) in a report released on ...

Research analysts at HC Wainwright increased their Q1 2025 earnings per share (EPS) estimates for Surrozen in a report issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now anticipates ...

H.C. Wainwright raised the firm’s price target on Compass Therapeutics (CMPX) to $24 from $10 and keeps a Buy rating on the shares. The company ...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

H.C. Wainwright says Novo Nordisk’s (NVO) REDEFINE-2 results reinforce Viking Therapeutics’ (VKTX) VK2735’s potential in obesity and beyond. Assuming full adherence, Novo’s CagriSema ...

On Friday, H.C. Wainwright’s analysts reaffirmed a Buy rating on Altimmune (NASDAQ:ALT) shares, with a steady price target of $12.00. According to InvestingPro data, the stock is currently trading ...

On Monday, H.C. Wainwright reaffirmed its Buy rating and $3.00 price target on RenovoRx Inc. (NASDAQ: RNXT) following the company’s strategic update and a fireside chat. With the stock currently ...